Jazz Pharmaceuticals (JAZZ) PT Raised to $235 at Barclays
Tweet
Share
E-mailGet Alerts JAZZ Hot Sheet
Price: $248.36 --0%
Rating Summary:
33 Buy, 5 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 6 | Down: 10 | New: 23
Rating Summary:
33 Buy, 5 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 6 | Down: 10 | New: 23
Join SI Premium – FREE
Barclays analyst Balaji Prasad raised the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $235.00 (from $233.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Biotech funding rises 75% this year as M&A activity continues
- Ollie's Bargain Outlet (OLLI) PT Lowered to $113 at Piper Sandler, 'Favorable Risk/Reward for 2H '
- Imdex Limited (IMD:AU) (IMDXF) PT Lowered to AUD5.05 at UBS
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
